{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:39:34Z","timestamp":1793893174057,"version":"4.8.0"},"reference-count":112,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine &amp; Growth Factor Reviews"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.cytogfr.2026.07.007","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T23:24:47Z","timestamp":1786577087000},"page":"110-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Cytokine circuitries as determinants of response, resistance, and toxicity across cancer immunotherapy platforms"],"prefix":"10.1016","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6038-7337","authenticated-orcid":false,"given":"Arpita","family":"Mukherjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cytogfr.2026.07.007_bib1","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s40001-024-01711-z","article-title":"The paradoxical role of cytokines and chemokines at the tumor microenvironment: a comprehensive review","volume":"29","author":"Abdul-Rahman","year":"2024","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1701405","article-title":"The \u201cdouble-edged sword\u201d effect of cytokines in cancer: coexisting opportunities and challenges","volume":"16","author":"Yin","year":"2025","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.cytogfr.2026.07.007_bib3","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.trecan.2025.04.014","article-title":"Immunocytokines and cytokine neutralization for cancer immunotherapy","volume":"11","author":"Berraondo","year":"2025","journal-title":"Trends Cancer"},{"issue":"11","key":"10.1016\/j.cytogfr.2026.07.007_bib4","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/s41573-024-01026-y","article-title":"Targeting cytokine networks in neuroinflammatory diseases","volume":"23","author":"Becher","year":"2024","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib5","article-title":"Protein engineering to overcome limitations of key cytokines in cancer immunotherapy: current approaches and future perspectives","volume":"28","author":"Salazar","year":"2025","journal-title":"Immunoeng. Technol."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116203","article-title":"Tumor immunotherapy resistance: Revealing the mechanism of PD-1\/PD-L1-mediated tumor immune escape","volume":"171","author":"Cui","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib7","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol. Cancer"},{"issue":"5","key":"10.1016\/j.cytogfr.2026.07.007_bib8","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1089\/jir.2024.0259","article-title":"IFN-\u03b3 approaches in tumor suppression, its challenges, and future directions: a review of recent advances","volume":"45","author":"Ataherian","year":"2025","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib9","first-page":"1","article-title":"Cytokine-driven cancer immune evasion mechanisms","volume":"396","author":"Arenas","year":"2025","journal-title":"Int. Rev. Cell. Mol. Biol."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1601773","article-title":"Tumor-infiltrating lymphocytes in cancer immunotherapy: from chemotactic recruitment to translational modeling","volume":"16","author":"Kraja","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.07.007_bib11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.cytogfr.2026.07.007_bib12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/intimm\/dxad033","article-title":"Cytokine signaling in chimeric antigen receptor T-cell therapy","volume":"36","author":"Kagoya","year":"2024","journal-title":"Int. Immunol."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2025.156888","article-title":"The role of cytokines in shaping the future of cancer immunotherapy","volume":"189","author":"Safaei","year":"2025","journal-title":"Cytokine"},{"issue":"8","key":"10.1016\/j.cytogfr.2026.07.007_bib14","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-018-0085-8","article-title":"A natural killer\u2013dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments","volume":"24","author":"Barry","year":"2018","journal-title":"Nat. Med."},{"issue":"20","key":"10.1016\/j.cytogfr.2026.07.007_bib15","doi-asserted-by":"crossref","first-page":"9959","DOI":"10.3390\/ijms26209959","article-title":"Roles of tumor-infiltrating lymphocytes and antitumor immune responses as predictive and prognostic markers in patients with breast cancer receiving neoadjuvant chemotherapy","volume":"26","author":"Kim","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"18","key":"10.1016\/j.cytogfr.2026.07.007_bib16","doi-asserted-by":"crossref","first-page":"4734","DOI":"10.1016\/j.cell.2021.08.003","article-title":"Spatially organized multicellular immune hubs in human colorectal cancer","volume":"184","author":"Pelka","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.cytogfr.2026.07.007_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1548234","article-title":"Deciphering T-cell exhaustion in the tumor microenvironment: paving the way for innovative solid tumor therapies","volume":"16","author":"Nair","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib18","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12943-025-02380-0","article-title":"Demystifying the cGAS-STING pathway: precision regulation in the tumor immune microenvironment","volume":"24","author":"Wang","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.cytogfr.2026.07.007_bib19","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-026-00939-7","article-title":"The formation and function of tertiary lymphoid structures","volume":"14","author":"Zhang","year":"2026","journal-title":"Biomark. Res."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13045-025-01754-7","article-title":"Tertiary lymphoid structures in cancer: spatiotemporal heterogeneity, immune orchestration, and translational opportunities","volume":"18","author":"Deng","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib21","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41698-025-00857-1","article-title":"Quantifying and interpreting biologically meaningful spatial signatures within tumor microenvironments","volume":"9","author":"Jing","year":"2025","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1547466","article-title":"The role of type I interferon signaling in myeloid anti-tumor immunity","volume":"16","author":"Meyer","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib23","article-title":"Terminally exhausted CD8+ T cells in solid tumors: biology, biomarker potential and translational tools for precision oncology","volume":"16","author":"Guo","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib24","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00262-025-04183-0","article-title":"Dynamic remodeling of tertiary lymphoid structures in response to cancer therapy: a recent review","volume":"74","author":"Tan","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"issue":"6","key":"10.1016\/j.cytogfr.2026.07.007_bib25","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/s43018-025-00986-3","article-title":"The tumor microenvironment\u2019s role in the response to immune checkpoint blockade","volume":"6","author":"Aliazis","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.cytogfr.2026.07.007_bib26","article-title":"Immunotherapy biomarkers in brain metastases: insights into tumor microenvironment dynamics","volume":"16","author":"Li","year":"2025","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.cytogfr.2026.07.007_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.112897","article-title":"Simulating CD8 T cell exhaustion: a comprehensive approach","volume":"28","author":"Manrique-Rinc\u00f3n","year":"2025","journal-title":"iScience"},{"issue":"3","key":"10.1016\/j.cytogfr.2026.07.007_bib28","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10585-023-10246-2","article-title":"Dissecting the tumor microenvironment in response to immune checkpoint inhibitors via single-cell and spatial transcriptomics","volume":"41","author":"Liu","year":"2024","journal-title":"Clin. Exp. Metastas."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2026.02.003","article-title":"Persistent spatial immune responses in glioblastoma following oncolytic virus therapy","volume":"89","author":"Ma","year":"2026","journal-title":"Cytokine Growth Factor. Rev."},{"issue":"6","key":"10.1016\/j.cytogfr.2026.07.007_bib30","doi-asserted-by":"crossref","DOI":"10.4110\/in.2025.25.e43","article-title":"Cytokine engineering in CAR-T cell therapy: next-generation strategies","volume":"25","author":"Kim","year":"2025","journal-title":"Immune Netw."},{"issue":"6753","key":"10.1016\/j.cytogfr.2026.07.007_bib31","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1126\/science.ads8473","article-title":"vivo CAR T cell generation to treat cancer and autoimmune disease","volume":"388","author":"Hunter","year":"2025","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.cytogfr.2026.07.007_bib32","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltae005","article-title":"Bispecific T-cell engagers for the recruitment of T cells in solid tumors: a literature review","volume":"5","author":"Dewaele","year":"2025","journal-title":"Immunother. Adv."},{"issue":"2","key":"10.1016\/j.cytogfr.2026.07.007_bib33","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/cpt.70020","article-title":"Clinical pharmacology characterization of bispecific T-cell engagers: a summary based on FDA approvals","volume":"119","author":"Wang","year":"2026","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib34","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/s12935-025-03980-y","article-title":"The role of NK cells in regulating tumor immunity: current state, challenges and future strategies","volume":"25","author":"Zhu","year":"2025","journal-title":"Cancer Cell. Int."},{"issue":"11","key":"10.1016\/j.cytogfr.2026.07.007_bib35","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.32604\/or.2025.071708","article-title":"CD47-targeted therapy in cancer immunotherapy: at a crossroads of promise and challenge","volume":"33","author":"Guo","year":"2025","journal-title":"Oncol. Res."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1679092","article-title":"Bispecific immunotherapy based on antibodies, T-cell receptors, and aptamers: mechanisms of action, adverse effects, and future perspectives","volume":"16","author":"Lopatnikova","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib37","article-title":"Multimodal cell-cell communication driving CD8+ T cell dysfunction and immune evasion","volume":"16","author":"Chen","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1749965","article-title":"Targeting MDSCs in cancer: emerging immunotherapeutic and metabolic strategies","volume":"17","author":"Dash S","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1661545","article-title":"Infiltration characteristics and regulatory mechanisms of CD8+ T lymphocytes in solid tumors: spatial distribution, biological functions, and interactions with the immune microenvironment","volume":"16","author":"Ouyang","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.07.007_bib40","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12943-018-0928-4","article-title":"Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape","volume":"18","author":"Jiang","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.cytogfr.2026.07.007_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1630488","article-title":"Systems immunology: When systems biology meets immunology","volume":"16","author":"Alfonso-Gonz\u00e1lez","year":"2025","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.cytogfr.2026.07.007_bib42","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib43","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.cytogfr.2025.01.003","article-title":"Insights into IL-6\/JAK\/STAT3 signaling in the tumor microenvironment: Implications for cancer therapy","volume":"85","author":"Thuya","year":"2025","journal-title":"Cytokine Growth Factor. Rev."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.07.007_bib44","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3390\/cells10010100","article-title":"Inflammatory cytokines in cancer: comprehensive understanding and clinical progress in gene therapy","volume":"10","author":"Lan","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.cytogfr.2026.07.007_bib45","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fonc.2018.00049","article-title":"Targeting macrophages in cancer: from bench to bedside","volume":"8","author":"Poh","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib46","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13046-025-03377-9","article-title":"Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy","volume":"44","author":"Yang","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib47","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12943-024-02208-3","article-title":"Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy","volume":"24","author":"He","year":"2025","journal-title":"Mol. Cancer"},{"issue":"10","key":"10.1016\/j.cytogfr.2026.07.007_bib48","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41571-019-0222-4","article-title":"Tumour-associated neutrophils in patients with cancer","volume":"16","author":"Shaul","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.cytogfr.2026.07.007_bib49","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2159-8290.CD-23-1380","article-title":"Spatial architecture of myeloid and T cells orchestrates immune evasion and clinical outcome in lung cancer","volume":"14","author":"Enfield","year":"2024","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.cytogfr.2026.07.007_bib50","doi-asserted-by":"crossref","first-page":"213","DOI":"10.15430\/JCP.2020.25.4.213","article-title":"Recent advances in the development of TGF-\u03b2 signaling inhibitors for anticancer therapy","volume":"25","author":"Lee","year":"2020","journal-title":"J. Cancer Prev."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1698088","article-title":"TGF-\u03b2\u2013driven T-cell exclusion in ovarian cancer: single-cell and spatial transcriptomic views of immune low-response states","volume":"16","author":"He","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib52","first-page":"114","article-title":"Mapping immunosuppressive terrain in high-grade serous ovarian cancer: tumor-intrinsic, stromal, and spatial drivers of therapy response","volume":"10","author":"Liu","year":"2026","journal-title":"npj Precis. Oncol."},{"issue":"6","key":"10.1016\/j.cytogfr.2026.07.007_bib53","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41568-026-00915-1","article-title":"Striking the right balance with type I interferon signalling in cancer","volume":"26","author":"Chadwick","year":"2026","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.cytogfr.2026.07.007_bib54","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41568-025-00883-y","article-title":"Epigenetic regulation of T cell exhaustion in cancer","volume":"26","author":"Kang","year":"2026","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.cytogfr.2026.07.007_bib55","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13046-026-03656-z","article-title":"Rewiring tumor cytokine networks to enhance immune checkpoint blockade: mechanisms, engineering, and clinical translation","volume":"45","author":"Wang","year":"2026","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib56","article-title":"Immune-related adverse events in immunotherapy: challenges in diagnosis, monitoring, and management","volume":"14","author":"Siddiqui","year":"2025","journal-title":"Toxicol. Rep."},{"issue":"12","key":"10.1016\/j.cytogfr.2026.07.007_bib57","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s40265-025-02243-4","article-title":"Long-term toxicities of immune checkpoint inhibitors","volume":"85","author":"Abraham","year":"2025","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.cytogfr.2026.07.007_bib58","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1161\/CIRCRESAHA.124.325652","article-title":"Novel therapeutic approach targeting CXCR3 to treat immunotherapy myocarditis","volume":"136","author":"Huang","year":"2025","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.07.007_bib59","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2023.2261326","article-title":"Interleukin-17 signaling influences CD8+ T cell immunity and tumor progression according to the IL-17 receptor subunit expression pattern in cancer cells","volume":"12","author":"Rodriguez","year":"2023","journal-title":"Oncoimmunology"},{"issue":"20","key":"10.1016\/j.cytogfr.2026.07.007_bib60","doi-asserted-by":"crossref","DOI":"10.1172\/JCI184310","article-title":"Distinguishing between help and harm: Helper T cell subsets and immune-related adverse events","volume":"134","author":"Haugh","year":"2024","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.cytogfr.2026.07.007_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2026.120115","article-title":"The role of cytokines in cytokine release syndrome (CRS) after CAR T cell therapy","volume":"1873","author":"Gabriel","year":"2026","journal-title":"Biochim. Biophys. Acta Mol. Cell. Res."},{"issue":"21","key":"10.1016\/j.cytogfr.2026.07.007_bib62","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1158\/1078-0432.CCR-22-3667","article-title":"Dissecting the mechanisms underlying the cytokine release syndrome (CRS) mediated by T-cell bispecific antibodies","volume":"29","author":"Leclercq-Cohen","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.cytogfr.2026.07.007_bib63","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3892\/etm.2024.12712","article-title":"Cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome in a melanoma patient treated with adjuvant pembrolizumab","volume":"28","author":"Ochenduszko","year":"2024","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib64","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s44272-025-00044-0","article-title":"Management of cytokine release syndrome (CRS) following CAR T-cell therapy: a comprehensive review","volume":"4","author":"Zhang","year":"2025","journal-title":"Clin. Cancer Bull."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib65","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1186\/s12885-025-14733-5","article-title":"Adverse drug events of immune checkpoint inhibitors - a retrospective, descriptive real-world data analysis","volume":"25","author":"Auch","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cytogfr.2026.07.007_bib66","article-title":"Neurologic complications of immune checkpoint inhibitors: a comprehensive review","volume":"192","author":"Zivari Lashkajani","year":"2025","journal-title":"Biomed. Pharmacother."},{"issue":"6","key":"10.1016\/j.cytogfr.2026.07.007_bib67","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70775","article-title":"Mapping immunity with cutting-edge spatial biology and tissue cytometry innovations","volume":"7","author":"C\u00e1rdenas-Piedra","year":"2026","journal-title":"MedComm"},{"issue":"8","key":"10.1016\/j.cytogfr.2026.07.007_bib68","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41571-020-0352-8","article-title":"Moving towards personalized treatments of immune-related adverse events","volume":"17","author":"Esfahani","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.07.007_bib69","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41416-018-0155-1","article-title":"Immune dysregulation in cancer patients developing immune-related adverse events","volume":"120","author":"Khan","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.cytogfr.2026.07.007_bib70","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41590-024-01768-2","article-title":"Integrating single-cell multi-omics and prior biological knowledge for a functional characterization of the immune system","volume":"25","author":"Sch\u00e4fer","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib71","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s12943-025-02426-3","article-title":"Single-cell multi-omics in cancer immunotherapy: from tumor heterogeneity to personalized precision treatment","volume":"24","author":"Le","year":"2025","journal-title":"Mol. Cancer"},{"issue":"8","key":"10.1016\/j.cytogfr.2026.07.007_bib72","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.cell.2026.03.025","article-title":"Mapping intratumor heterogeneity across layers for advancing immunotherapy","volume":"189","author":"Marine","year":"2026","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.cytogfr.2026.07.007_bib73","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ccell.2025.12.009","article-title":"Spatial omics at the forefront: emerging technologies, analytical innovations, and clinical applications","volume":"44","author":"Liu","year":"2025","journal-title":"Cancer Cell."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.07.007_bib74","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41568-023-00635-w","article-title":"How chemokines organize the tumour microenvironment","volume":"24","author":"Mempel","year":"2024","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.cytogfr.2026.07.007_bib75","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41580-024-00768-2","article-title":"Profiling cell identity and tissue architecture with single-cell and spatial transcriptomics","volume":"26","author":"Gulati","year":"2025","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"issue":"11","key":"10.1016\/j.cytogfr.2026.07.007_bib76","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41581-024-00841-1","article-title":"Spatial transcriptomics in health and disease","volume":"20","author":"Jain","year":"2024","journal-title":"Nat. Rev. Nephrol."},{"issue":"2","key":"10.1016\/j.cytogfr.2026.07.007_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.lmd.2025.100076","article-title":"Application of spatial and single-cell omics in tumor immunotherapy biomarkers","volume":"2","author":"Zhang","year":"2025","journal-title":"LabMed Discov."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib78","article-title":"Decoding immunotherapy response through computational modeling","volume":"17","author":"Li","year":"2026","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.cytogfr.2026.07.007_bib79","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41416-025-03075-5","article-title":"Spatial omics technology potentially promotes the progress of tumor immunotherapy","volume":"133","author":"Lan","year":"2025","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.cytogfr.2026.07.007_bib80","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10555-025-10304-z","article-title":"Spatial omics: applications and utility in profiling the tumor microenvironment","volume":"44","author":"See","year":"2025","journal-title":"Cancer Metastas. Rev."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib81","article-title":"Applications of single-cell omics in tumor immunology","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.cytogfr.2026.07.007_bib82","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ccell.2018.03.005","article-title":"Emerging concepts for immune checkpoint blockade-based combination therapies","volume":"33","author":"Zappasodi","year":"2018","journal-title":"Cancer Cell."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.07.007_bib83","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-025-01722-1","article-title":"Application of single-cell and spatial omics in deciphering cellular hallmarks of cancer drug response and resistance","volume":"18","author":"Cheng","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib84","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41423-026-01424-9","article-title":"Adaptive resistance in cancer immunotherapy","volume":"23","author":"Yang","year":"2026","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2025.102556","article-title":"Autoimmune-related adverse events induced by immune checkpoint inhibitors","volume":"94","author":"Sun","year":"2025","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2025.101956","article-title":"The pathogenesis of neurological immune-related adverse events following immune checkpoint inhibitor therapy","volume":"78","author":"Lerch","year":"2025","journal-title":"Semin. Immunol."},{"issue":"7","key":"10.1016\/j.cytogfr.2026.07.007_bib87","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.trecan.2023.04.002","article-title":"Immune mechanisms of toxicity from checkpoint inhibitors","volume":"9","author":"Wang","year":"2023","journal-title":"Trends Cancer"},{"issue":"10","key":"10.1016\/j.cytogfr.2026.07.007_bib88","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41573-023-00746-x","article-title":"Strategies to therapeutically modulate cytokine action","volume":"22","author":"Leonard","year":"2023","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.07.007_bib89","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/imr.13270","article-title":"The evolving landscape of immune-related adverse events that follow immune checkpoint immunotherapy in cancer patients","volume":"318","author":"Villani","year":"2023","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib90","article-title":"Protein engineering to overcome limitations of key cytokines in cancer immunotherapy: current approaches and future perspectives","volume":"28","author":"Salazar","year":"2025","journal-title":"Immuno-Oncol. Technol."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.07.007_bib91","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.07.007_bib92","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10238-026-02066-x","article-title":"Cytokine-mediated tumor sensitization: mechanistic frameworks and therapeutic opportunities in cancer immunotherapy","volume":"26","author":"Aghaei","year":"2026","journal-title":"Clin. Exp. Med."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.07.007_bib93","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/imr.13272","article-title":"Type I interferon and cancer","volume":"321","author":"Holicek","year":"2024","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.surg.2025.109847","article-title":"Research advances in stimulator of interferon genes (STING) agonists for cancer immunotherapy","volume":"190","author":"Shen","year":"2026","journal-title":"Surgery"},{"key":"10.1016\/j.cytogfr.2026.07.007_bib95","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.cytogfr.2026.05.004","article-title":"Designing next-generation interleukin immunotherapy: A cytokine-guided framework for precision cancer therapy","volume":"90","author":"Wang","year":"2026","journal-title":"Cytokine Growth Factor. Rev."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib96","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-026-01280-8","article-title":"Progress in the development of cytokine armoured CAR T cells","author":"Prasad","year":"2026","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib97","doi-asserted-by":"crossref","DOI":"10.1111\/imcb.70112","article-title":"Cytokine armored CAR T cells for cancer immunotherapy","author":"Sek","year":"2026","journal-title":"Immunol. Cell. Biol."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib98","doi-asserted-by":"crossref","DOI":"10.1039\/D6CB00005C","article-title":"Recent progress in cGAS-STING agonist design and mechanisms of cancer immune modulation","volume":"7","author":"Wang","year":"2026","journal-title":"RSC Chem. Biol."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib99","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s13402-026-01199-1","article-title":"Next-generation neoantigen mRNA vaccines: immuno-engineering strategies for precision cancer immunotherapy","volume":"49","author":"Li","year":"2026","journal-title":"Cell Oncol."},{"issue":"6","key":"10.1016\/j.cytogfr.2026.07.007_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.humimm.2026.111728","article-title":"CAR-NK cell therapy for overcoming antigen heterogeneity and immunosuppressive tumor microenvironments","volume":"87","author":"Qutub","year":"2026","journal-title":"Hum. Immunol."},{"issue":"10","key":"10.1016\/j.cytogfr.2026.07.007_bib101","doi-asserted-by":"crossref","DOI":"10.1002\/eji.70073","article-title":"From histology to high-resolution mapping: The rise of spatial omics in immunology","volume":"55","author":"De Giovanni","year":"2025","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbpa.2026.102670","article-title":"Next-generation interleukin-enhanced immunotherapies: from molecular engineering to armored T-cell architectures","volume":"92","author":"Li","year":"2026","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"29","key":"10.1016\/j.cytogfr.2026.07.007_bib103","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202520806","article-title":"A guide for spatial omics technologies: innovation, evaluation, and application","volume":"13","author":"Wu","year":"2026","journal-title":"Adv. Sci."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2026.101320","article-title":"BRCA1 deficiency induces NF\u03baB-dependent type-I interferon signaling in fallopian tube epithelial cells","volume":"78","author":"Madaan","year":"2026","journal-title":"Neoplasia"},{"key":"10.1016\/j.cytogfr.2026.07.007_bib105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Yin","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib106","article-title":"Multi-omics biomarkers for predicting resistance, hyperprogression, and immune-related toxicity during PD-1\/PD-L1 therapy in lung cancer: a literature review","volume":"17","author":"Hu","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib107","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40425-018-0376-0","article-title":"Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers","volume":"6","author":"Mushtaq","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.cytogfr.2026.07.007_bib108","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10875-025-01929-4","article-title":"The targets of immune adverse events in cancer immunotherapy by combined check-point inhibitors resemble those seen in IPEX patients","volume":"45","author":"Moraes-Fontes","year":"2025","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib109","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1794130","article-title":"Multidimensional tumor heterogeneity and its role in therapeutic resistance","volume":"17","author":"Mubin","year":"2026","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.cytogfr.2026.07.007_bib110","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41571-025-01109-8","article-title":"Discovery of predictive biomarkers for cancer therapy through computational approaches","volume":"23","author":"Wang","year":"2026","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.cytogfr.2026.07.007_bib111","article-title":"Correlation does not equal causation: the imperative of causal inference in machine learning models for immunotherapy","volume":"16","author":"Wang","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.cytogfr.2026.07.007_bib112","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10238-025-01965-9","article-title":"AI-driven multi-omics integration in precision oncology: bridging the data deluge to clinical decisions","volume":"26","author":"Hsu","year":"2025","journal-title":"Clin. Exp. Med."}],"container-title":["Cytokine &amp; Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610126000596?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359610126000596?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:32:14Z","timestamp":1788881534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359610126000596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":112,"alternative-id":["S1359610126000596"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2026.07.007","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytokine circuitries as determinants of response, resistance, and toxicity across cancer immunotherapy platforms","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2026.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}